Best GLP-1 Weight Loss Drugs

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications that have shown significant efficacy in promoting weight loss. These drugs mimic the action of the natural GLP-1 hormone, which helps regulate blood sugar and appetite. While originally developed for managing type 2 diabetes, certain GLP-1 agonists are now approved for weight management in individuals without diabetes.

Most Effective GLP-1 Weight Loss Medications:

1. Tirzepatide (Zepbound): Tirzepatide is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. Clinical trials have demonstrated that tirzepatide can lead to an average weight loss of up to 22.5% of body weight, making it one of the most effective options available. (drugs.com)

2. Semaglutide (Wegovy): Semaglutide is a GLP-1 receptor agonist that has been shown to result in an average weight loss of approximately 15–16% of body weight. It is available in both injectable (Wegovy) and oral (Rybelsus) forms. (drugs.com)

3. Liraglutide (Saxenda): Liraglutide is another GLP-1 receptor agonist that has demonstrated effectiveness in weight loss, with studies indicating an average weight loss of around 8% of body weight. (glp-1.com)

Considerations When Choosing a GLP-1 Weight Loss Medication:

• Efficacy: Tirzepatide has shown the highest efficacy in weight loss among GLP-1 agonists.

• Formulation and Administration: Medications are available in various forms, including once-weekly injections (e.g., Wegovy, Zepbound), daily injections (e.g., Saxenda), and oral tablets (e.g., Rybelsus). The choice may depend on personal preference and convenience.

• Side Effects: Common side effects of GLP-1 agonists include nausea, vomiting, diarrhea, abdominal pain, and constipation. These are usually mild and decrease over time. (who.int)

• Cost and Insurance Coverage: The cost of these medications can vary, and insurance coverage may differ. It's important to check with your insurance provider and consider generic options if available.

Recent Developments:

In December 2025, the U.S. Food and Drug Administration approved the first daily oral version of the weight-loss drug Wegovy, marking a significant step in obesity treatment. This pill offers an alternative to weekly injections, delivering similar weight-loss results—between 16% and 17% of body weight. (time.com)

Additionally, Eli Lilly is developing a triple agonist called retatrutide, which activates GLP-1, GIP, and glucagon receptors. In clinical trials, participants on the highest dose of retatrutide lost nearly 30% of their body weight over 68 weeks, indicating a promising advancement in weight loss therapies. (scientificamerican.com)

Conclusion:

GLP-1 receptor agonists, particularly tirzepatide, semaglutide, and liraglutide, have proven effective in promoting weight loss. The choice of medication should be personalized, considering factors such as efficacy, administration method, side effects, cost, and individual health conditions. Consulting with a healthcare provider is essential to determine the most appropriate treatment plan.

Recent Developments in GLP-1 Weight Loss Medications:

• US regulators approve Wegovy pill for weight loss, Published on Monday, December 22
• A Pill Version of Wegovy Hits Pharmacies, Published on Monday, January 05
• Wegovy now comes in pill form - here's how it works, Published on Thursday, January 22

Based on the latest research and clinical data, here are the best GLP-1 weight loss drugs currently available and in development:

Currently Approved GLP-1 Weight Loss Drugs

Most Effective: Tirzepatide (Zepbound)

The most effective GLP-1 drug for weight loss currently (as of early 2026) is tirzepatide, marketed under the names Zepbound (for weight loss) and Mounjaro (for diabetes)
.
A 2024 systematic review and meta-analysis that included 53 studies lasting between 12 and 78 weeks and 21,349 patients found that compared with placebo, tirzepatide worked the best for weight loss. On average, patients taking tirzepatide lost about 8.5 kg (19 lbs)
.
According to clinical trials cited by multiple sources including NBC News, tirzepatide (a GIP/GLP-1 dual agonist) showed approximately 21% to 22.5% mean weight loss on its highest dose after 72 weeks
.

Second Most Effective: Semaglutide (Wegovy)

This was followed by semaglutide, liraglutide, dulaglutide, and then exenatide. Those taking semaglutide lost about 3 kg (6.6 lbs)
.
A 2025 head-to-head trial studying tirzepatide vs. semaglutide for obesity showed tirzepatide produced significantly greater reductions in body weight and waist circumference over 72 weeks compared to semaglutide
.

Other FDA-Approved Options:

• Saxenda (liraglutide) -
  Can be used in adults with a body mass index (BMI) of 30 kg/m2 or greater, or 27 kg/m2 or greater with at least one weight-related health condition

New Oral Options (2026)

Oral Wegovy (Semaglutide Pills)

The Food and Drug Administration approved the Wegovy pill on December 22. It has the same active ingredient as Ozempic and Wegovy, which is semaglutide, and studies show it's about as effective as the injections when it comes to weight loss
.
Starting dose (1.5 mg) listed at $149/month for cash-pay patients
.

Upcoming: Orforglipron (Eli Lilly)

March 2026 (Expected): FDA decision anticipated on Eli Lilly's orforglipron, an oral GLP-1 that does not require dietary restrictions. According to Reuters, Eli Lilly expects FDA approval for its oral obesity drug in March 2026
.
According to CNN, Eli Lilly's experimental oral drug showed 11% mean weight loss over 72 weeks on its highest dose in clinical trials
.

Next-Generation Drugs in Development

CagriSema (Novo Nordisk)

In trials, participants taking CagriSema lost about 23 percent of their body weight in 68 weeks
.
A representative for Novo Nordisk told Scientific American that the company hopes to see FDA review in 2026
.

Retatrutide (Eli Lilly)

Eli Lilly, the manufacturer of retatrutide, estimates that the medication may help people lose up to an average of 29% of their initial body weight after about 68 weeks (15 months)
.

Important Considerations

Real-World vs. Clinical Results:

Recent studies show a clear gap between clinical trial results and real-world outcomes for GLP-1 agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro). Despite headline-grabbing clinical results (up to 22% weight loss in trials), average weight reduction in routine care is typically 2–8% after a year, with only about one third of patients achieving greater than 5% loss
.

Patient-Specific Factors:

Some GLP-1 drugs might be recommend over others depending on patient factors like other health conditions and preferences. For example: Tirzepatide (Zepbound) shows the greatest mean weight loss and is also approved for obstructive sleep apnea, but semaglutide (Wegovy) is preferred for those with cardiovascular or kidney complications
.

The choice of the "best" GLP-1 drug depends on individual factors including medical history, preferences for injection vs. oral medication, cost considerations, and specific health conditions. It's essential to consult with a healthcare provider to determine the most appropriate option for your specific situation.

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications initially developed to treat type 2 diabetes, but have been found to be effective for weight loss. These drugs mimic the GLP-1 hormone in the body, which helps control insulin and blood glucose levels, promotes feelings of fullness, slows digestion, and reduces appetite and cravings.

As of early 2026, here's a breakdown of some of the top GLP-1 weight loss drugs:

• Tirzepatide (Zepbound, Mounjaro): Tirzepatide is considered the most effective GLP-1 drug for weight loss. Clinical trials have demonstrated average weight losses of up to 22.5% of body weight. It is marketed as Zepbound for weight loss and Mounjaro for type 2 diabetes. Tirzepatide is a dual GLP-1 and GIP receptor agonist.
• Semaglutide (Wegovy, Ozempic, Rybelsus): Semaglutide is another highly effective GLP-1 receptor agonist. Wegovy is FDA-approved for weight loss, while Ozempic is approved to improve blood sugar control in patients with type 2 diabetes. Rybelsus is an oral tablet form of semaglutide. Clinical trials have shown that semaglutide averages up to 15-16% weight loss.
• Liraglutide (Saxenda, Victoza): Liraglutide is a GLP-1 receptor agonist that is administered as a daily injection. Saxenda is approved for weight loss, while Victoza is approved for type 2 diabetes. It generally results in a more modest weight reduction of around 4-5%.

While all GLP-1 drugs can lead to weight loss, Wegovy, Saxenda, and Zepbound are specifically FDA-approved for weight management.

It's important to note that GLP-1 medications are not a "magic fix" and should be combined with healthy habits like balanced meals and regular physical activity. Also, these medications may have side effects, the most common being gastrointestinal issues.

Tirzepatide (Zepbound) and semaglutide (Wegovy) are the leading GLP-1 weight loss drugs based on clinical trial data, with Zepbound showing up to 22.5% average weight loss and Wegovy up to 14.9-16.6%. These FDA-approved GLP-1 receptor agonists (and dual GLP-1/GIP agonist for tirzepatide) mimic hormones that reduce appetite, slow gastric emptying, and promote sustained weight loss when combined with diet and exercise.

Key GLP-1 Drugs and Weight Loss Results

Drug (Active Ingredient)	Average Weight Loss	FDA Approval for Weight Loss	Administration	Notes
Zepbound (tirzepatide)	Up to 22.5%	Yes, for obesity (BMI ≥30) or overweight (BMI ≥27) with conditions	Weekly injection	Highest reported loss; also Mounjaro for diabetes.
Wegovy (semaglutide)	14.9% (injection); 16.6% (pill)	Yes, adults and children ≥12	Weekly injection or daily oral pill (launched 2026)	Ozempic (same ingredient) not approved for weight loss but used off-label (6% loss).
Saxenda (liraglutide)	~5-8%	Yes	Daily injection	Lower efficacy than newer options.

Results vary by individual factors like BMI, adherence, and trial duration (e.g., 1-1.5 years). All require medical evaluation for suitability, considering side effects like nausea, gastrointestinal issues, or risks for those with thyroid cancer history.

Emerging Options (as of 2026)

• Orforglipron (Eli Lilly oral GLP-1): ~11.2% loss at 72 weeks; stable for food intake; phase 3 completed 2025.
• CagriSema (Novo Nordisk; semaglutide + amylin analog): ~20-23% loss at 68 weeks; head-to-head vs. tirzepatide trial ending 2026.
• Amycretin (Novo Nordisk dual agonist): 24.3% loss at 36 weeks (phase 2 injection).

Consult a healthcare provider for prescriptions, as access involves assessments (e.g., via Walgreens) and insurance varies. Ongoing trials address weight regain post-treatment.